BillionToOne
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1035 Obrien Dr, Menlo Park, California, ...Phone Number
(650) 460-2551Website
www.billiontoone.comRevenue
$397.4 MillionStock Symbol
BLLNIndustry
ZI Rank: 4
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
5
4
1
2
2
4
About BillionToOne
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. BillionToOne's flagship product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood.Explore more
BillionToOne Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BillionToOne your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BillionToOne has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
BillionToOne, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BillionToOne
Product Launch: Get notified when BillionToOne launches new products
Check out if BillionToOne is spiking on competitors!
Earning: See what the market has to say on BillionToOne recently announced quarterly report
Funding: Get notified immidiatlly once BillionToOne has new funding data
Click to see if BillionToOne had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at BillionToOne
Find 2 more new buyers
Compare Similar Companies to BillionToOne
Compare insights from companies similar to BillionToOne, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BillionToOne is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BillionToOne is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BillionToOne.
BillionToOne financials insights
Gather financial insights about BillionToOne, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$15M
2021
Series B
$55M
2022
Series C
$125M
Unspecified
$48.5M
2024
Series D
$130M
2025
IPO
$273.1M
BillionToOne Tech Stack
A closer look at the technologies used by BillionToOne
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Earnings, Contracts, Finance, Financial Transactions
Open Position
Open Position
BillionToOne News & Media
Billiontoone Q2 Earnings Call Highlights
Billiontoone (NASDAQ:BLLN) reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reitBillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.Does BillionToOne (BLLN) Have Another Major Growth Engine Beyond Prenatal Testing?
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisions MENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne,...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BillionToOne
Sign Up For FreeTo access detailed company insights
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. Billio... Read More
